FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
Not Approved
This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.
Evidence visual
Semax evidence and risk matrix
intermediate researcher fit
Evidence
Tier B-C
Risk
med high
Regulatory
not approved
WADA
unknown
FDA
flagged
Route
intranasal
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
Semax is an ACTH fragment analogue (ACTH(4-7) + Pro-Gly-Pro motif). Preclinical studies show increased BDNF expression in ischemia models. Human clinical use reports exist in stroke contexts with multi-mg daily intranasal dosing. FDA flagged semax in compounding safety context citing immunogenicity/impurity concerns and limited safety info for proposed routes. Not FDA-approved.
Decision path
Where Semax fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Semax belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Preclinical neurotrophic signaling including BDNF upregulation; modulation of neurotransmission and neurotrophic pathways proposed.
intranasal
Human stroke studies: multi-mg daily intranasal dosing. Animal: intranasal dosing with gene expression changes within hours.
Neurotrophic signaling; cognitive/neuroprotection narratives from Russian/EE clinical literature.
Gene expression changes within hours (animal); clinical stroke outcomes are longer-horizon.
No established label.
Immunogenicity/impurity concerns (FDA); limited Western safety framing.
Unknown; avoid claiming synergy with SSRIs/benzodiazepines without data.
Cost at a glance
Typical cycle cost
€13.76
Estimated monthly
€27.52
Protocol style
7-14 day burst
Short burst
Estimate confidence
High confidence
Assumes roughly 2 mg–6 mg per cycle, using 1 tracked affiliated listing.
Modeled as short nootropic blocks rather than a full-month protocol.
Age, sex, and monitoring
Life-stage fit
Usually discussed for adult cognitive or recovery support rather than youth-oriented performance enhancement.
Best fit age ranges: 35-44, 45-54, 55-64
Known Interactions
FDA notes limited safety-related information and compounding immunogenicity/impurity concerns for both.
CNS-active peptide combination; limited human safety basis.
Both are CNS-active experimental agents. Combination claims are stronger than the human safety evidence.
Mechanistically interesting but human combination data are weak; conservative caution.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Semax.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.